Financial Ratios

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia
BSE975.10-27.85 (-2.78 %)
PREV CLOSE ( ) 1002.95
OPEN PRICE ( ) 1003.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 16566
TODAY'S LOW / HIGH ( )966.25 1003.00
52 WK LOW / HIGH ( )532.05 1309
NSE976.25-26.7 (-2.66 %)
PREV CLOSE( ) 1002.95
OPEN PRICE ( ) 1003.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 976.25 (70)
VOLUME 158772
TODAY'S LOW / HIGH( ) 965.05 1003.90
52 WK LOW / HIGH ( )532.15 1309.9
Select year
ParticularsMar2024Mar2023Mar2022Mar2021Mar2020
Operational & Financial Ratios
   Earnings Per Share (Rs)1.993.145.0513.4720.16
   CEPS(Rs)5.035.867.3719.7426.90
   DPS(Rs)5.005.005.005.005.00
   Book NAV/Share(Rs)148.57151.61153.1080.52163.69
   Tax Rate(%)24.2237.074.9921.49-7.46
Margin Ratios
   Core EBITDA Margin(%)2.100.380.8915.7611.81
   EBIT Margin(%)9.1212.0713.1913.8413.86
   Pre Tax Margin(%)5.319.7911.6710.089.52
   PAT Margin (%)4.036.1611.097.9210.23
   Cash Profit Margin (%)10.1811.4916.1811.6113.65
Performance Ratios
   ROA(%)1.061.713.425.896.24
   ROE(%)1.322.064.3311.0312.98
   ROCE(%)2.643.674.3611.8210.10
   Asset Turnover(x)0.260.280.310.740.61
   Sales/Fixed Asset(x)0.800.891.432.221.53
   Working Capital/Sales(x)3.483.722.65-50.269.05
Efficiency Ratios
   Fixed Capital/Sales(x)1.251.120.700.450.66
   Receivable days89.0171.9165.740.0052.66
   Inventory Days131.29143.45162.540.0066.74
   Payable days160.53142.1195.8179.84131.60
Valuation Parameters
   PER(x)286.0588.9276.7450.5312.34
   PCE(x)113.1347.6652.6134.479.25
   Price/Book(x)3.831.842.538.451.52
   Yield(%)0.881.791.290.732.01
   EV/Net Sales(x)11.915.848.724.171.81
   EV/Core EBITDA(x)77.9533.5347.7223.7710.42
   EV/EBIT(x)130.5348.3466.1230.1113.03
   EV/CE(x)3.441.742.216.121.04
   M Cap / Sales11.525.488.514.001.26
Growth Ratio
   Net Sales Growth(%)-3.1411.62-73.22-13.71-8.69
   Core EBITDA Growth(%)-14.966.32-72.08-12.7236.42
   EBIT Growth(%)-26.792.19-74.48-13.8139.26
   PAT Growth(%)-36.67-38.01-62.47-33.21117.53
   EPS Growth(%)-36.67-37.90-62.47-33.21117.53
Financial Stability Ratios
   Total Debt/Equity(x)0.150.130.070.380.75
   Current Ratio(x)1.711.602.080.551.25
   Quick Ratio(x)0.920.730.800.550.77
   Interest Cover(x)2.395.298.713.683.19
   Total Debt/Mcap(x)0.040.070.030.050.50

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.